Tawfiq Nakhleh, DO
Interventional Pain Medicine · Clinton Twp, MINPI 1316905847
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 184 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $606 and has fallen 59.2% since, to $248 in 2025.
Across 184 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$344
- Lilly USA, LLC$332
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$331
- Collegium Pharmaceutical, Inc.$286
- Teva Pharmaceuticals USA, Inc.$181
- Virtus Pharmaceuticals LLC$148
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,93699%
- Education$211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 18 | $344 |
| Lilly USA, LLC | 15 | $332 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 28 | $331 |
| Collegium Pharmaceutical, Inc. | 19 | $286 |
| Teva Pharmaceuticals USA, Inc. | 20 | $181 |
| Virtus Pharmaceuticals LLC | 9 | $148 |
| Idorsia Pharmaceuticals US Inc | 9 | $142 |
| Pfizer | 8 | $120 |
| MDD US Operations, LLC | 8 | $115 |
| AbbVie | 6 | $105 |
| Vertex | 3 | $86 |
| Globus Medical | 3 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $74 |
| Boston Scientific | 3 | $72 |
| Eisai Inc. | 4 | $68 |
| Biodelivery Sciences International, Inc. | 4 | $66 |
| Amgen | 4 | $58 |
| Averitas Pharma Inc. | 1 | $44 |
| Orexo US, Inc. | 2 | $42 |
| Scilex Pharmaceuticals Inc. | 2 | $39 |
| Zyla Life Sciences, Inc. | 2 | $38 |
| GRT US Holding, Inc. | 2 | $32 |
| Abbott | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $18 |
| IBSA Pharma Inc. | 1 | $18 |
| Valinor Pharma, LLC | 1 | $17 |
| Sentynl Therapeutics, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Assertio Therapeutics, Inc. | 1 | $14 |
| USWM, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMGALITY$125
How this compares
$2,957 in reported general payments places this provider in the 60th percentile of 88 interventional pain medicine providers in Michigan.
See all interventional pain medicine providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 14 | $84,649 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,439 | $36,332 |
| Diclofenac Sodium | 38 | $35,252 |
| MovantikNaloxegol Oxalate | 75 | $30,087 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 613 | $17,381 |
| Morphine Sulfate ErMorphine Sulfate | 424 | $14,427 |
| Chlorzoxazone | 47 | $14,342 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 64 | $13,606 |
| Oxycodone Hcl | 607 | $12,882 |
| OxycontinOxycodone Hcl | 26 | $12,829 |
| Hysingla ErHydrocodone Bitartrate | 12 | $11,624 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 14 | $9,010 |
| Naproxen Sodium CrNaproxen Sodium | 13 | $8,716 |
| Gabapentin | 693 | $8,157 |
| Fentanyl | 79 | $8,002 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Morphine Sulfate, Buprenorphine Hcl | $21 | $16,885177 claims |
| Virtus Pharmaceuticals LLCLactulose | $148 | $93964 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 88 interventional pain medicine providers in Michigan.
Other interventional pain medicine in Clinton Twp
- Ryan PollinaSaint Clair Shores$144K
- Ariel MajjhooMonroe$124K
- Chad BrummettAnn Arbor$109K
- Anand ThakurClinton Township$102K
- Evan PeskinFlint$72K
- Richard FerroLansing$31K
- John ChatasAnn Arbor$29K
- Bryant IttiaraAllen Park$28K
- Fadi DellyWyandotte$25K
- Vincent RampersaudFlint$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.